Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Outcomes of patients with melioidosis treated with meropenem

Cheng, Allen C., Fisher, Dale A., Anstey, Nicholas M., Stephens, Dianne P., Jacups, Susan P. and Currie, Bart J. (2004). Outcomes of patients with melioidosis treated with meropenem. Antimicrobial Agents and Chemotherapy,48(5):1763-1765.

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 3
Google Scholar Search Google Scholar
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading Cheng_1467.pdf Published version application/pdf 141.95KB 59
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

Title Outcomes of patients with melioidosis treated with meropenem
Author Cheng, Allen C.
Fisher, Dale A.
Anstey, Nicholas M.
Stephens, Dianne P.
Jacups, Susan P.
Currie, Bart J.
Journal Name Antimicrobial Agents and Chemotherapy
Publication Date 2004
Volume Number 48
Issue Number 5
ISSN 0066-4804   (check CDU catalogue open catalogue search in new window)
Start Page 1763
End Page 1765
Total Pages 3
Place of Publication Washington, United States
Publisher American Society of Microbiology
Field of Research 0605 - Microbiology
1108 - Medical Microbiology
HERDC Category C1 - Journal Article (DEST)
Abstract Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for greater than or equal to14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.
Keywords tropical northern australia
colony-stimulating factor
septic shock
pseudomonas-pseudomallei
burkholderia-pseudomallei
therapy
susceptibility
ceftazidime
antibiotics
mortality
DOI http://dx.doi.org/10.1128/AAC.48.5.1763-1765.2004   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)


© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact digitisation@cdu.edu.au.

 
Versions
Version Filter Type
Access Statistics: 59 Abstract Views, 60 File Downloads  -  Detailed Statistics
Created: Fri, 12 Sep 2008, 08:35:25 CST by Administrator